Evidence map›Paper›PMID 38050902›Full record

ArticleGenes, chromosomes & cancer2024

Expanding the molecular landscape of undifferentiated sarcomas of bone with a novel EWSR1-SSX3 gene fusion.

Caterina Fumagalli, Ruth Orellana, Malena Ferré, Allan Gonzalez, Lluis Catasús, Tania Vázquez, Ana Sebio, Antonio López-Pousa, Jaume Llauger, Ana Peiró and 1 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in Genes, chromosomes & cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Identification of Novel/RareInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Caterina FumagalliDepartment of Pathology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0002-8614-7622
Ruth OrellanaDepartment of Pathology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Malena FerréDepartment of Pathology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Allan GonzalezDepartment of Pathology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Lluis CatasúsDepartment of Pathology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Tania VázquezDepartment of Pathology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Ana SebioDepartment of Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Antonio López-PousaDepartment of Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Jaume LlaugerDepartment of Radiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Ana PeiróDepartment of Traumatology and Orthopaedics, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Cristina R AntonescuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-9717-8205
Hospital de Sant Pau · ESMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Targeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI William D. Tap · 2018 to 2026
$21.5M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA217694
6 · The paper itself

Abstract

Undifferentiated sarcomas characterized by a primitive monomorphic round to spindle cell phenotype and often non-specific immunoprofile remain difficult to subclassify outside molecular analysis. The increased application of RNA sequencing in clinical practice led to significant advances and discoveries of novel gene fusions that furthered our understanding and refined classification of otherwise undifferentiated neoplasms. In this study, we report an undifferentiated round to spindle cell sarcoma arising in the femur of a 34-year-old female. The round to spindle tumor cells were arranged in short fascicles, with focal rosette formation, within a hyalinized stroma. The tumor immunoprofile included diffuse reactivity for CD99, SATB2, and TLE1 and patchy positivity for Cyclin D1, Keratin AE1/AE3, synaptophysin, and chromogranin. Other markers, such as EMA, SMA, desmin, S100, ERG, and WT1, were negative. Fluorescence in situ hybridization analysis for EWSR1 gene alterations showed a break-apart signal and targeted RNA sequencing revealed an EWSR1::SSX3 gene fusion. The patient received neoadjuvant chemotherapy followed by surgery and subsequently relapsed in less than a year with lung metastasis. Larger series are needed to determine if this fusion defines a novel subset of undifferentiated tumors or represents a genomic variant of already existing primitive round cell sarcoma categories, such as Ewing sarcoma or synovial sarcoma.

Indexed as

SarcomaSarcoma, EwingSoft Tissue NeoplasmsAdultBiomarkers, TumorFemaleGene FusionHumansIn Situ Hybridization, FluorescenceOncogene Proteins, FusionRNA-Binding Protein EWSTranscription FactorsBiomarkers, TumorEWSR1 protein, humanOncogene Proteins, FusionRNA-Binding Protein EWSTranscription FactorsEWSR1RNA-based next-generation sequencinground cellsarcomaSSX3undifferentiatedundifferentiated sarcoma of bone

Identifiers

PMID38050902
PMCPMC11364056
OpenAlexW4389337609

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.